Research Synthesis: Caloric Restriction Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Renumber and re-list the cross-outcome tensions so they form a coherent 1–N series; replace 'A fifth' with the correct ordinal or restructure.
2. Reconcile the 'claims' totals across the Findings Map, Evidence Snapshot, Results, and the abstract (e.g., 2669 vs 2679 vs per-source sums) so that the traceable claim count is internally consistent and externally verifiable.
3. Add explicit per-endpoint, per-study p-value and direction mapping (or cite the supplement table unambiguously) so that any cited statistic in the Results can be located in the source excerpt; in particular, clarify which endpoint in Razny 2021 the P = 0.003 corresponds to.
4. Recompute the 'severity 4' load-bearing tensions using per-endpoint (not per-source) direction codes, and label tensions as 'coding-artifact possible' where two sources disagree only because of the within-source coded direction rather than the within-endpoint coded direction.
5. Add a consistent, prominent flag for Jorgensen 2026 (veterinary RCT) wherever it appears in results tables and prose, and exclude it from any aggregate human cardiometabolic accounting or clearly mark its weight as preclinical context only.
6. Recheck direction coding for Houston 2018 and any other Look AHEAD-derived source; the bundle supports a clearer positive functional finding than the manuscript's coded direction reflects.
7. Remove or rephrase the Metabolic-Functional Tradeoff Framework so that it does not read as an unsupported organizing claim, or explicitly tie it to Ioannidis 2005 / a cited methodological reference.
8. Add a one-paragraph substantive background (biological/clinical rationale for CR) before the methodological framing so the Introduction reads as Background plus Methods rather than Methods only.

Major issues

• Cross-Domain Synthesis contains an internal numbering error: 'A fifth and overarching tension' follows the third tension, suggesting two tensions were dropped or miscounted, which undermines the structure's auditability.
• Several 'severity 4' load-bearing tensions are constructed by reading source-level direction codes against each other across different endpoints (e.g., Razny 2021 'negative on BMI' vs Lyngbaek 2024 'null on BMI') in a way that double-counts the same coded direction field and presents a partial conflict that may be an artifact of the direction-coding taxonomy rather than a substantive evidentiary disagreement. The reader cannot distinguish a real endpoint-level conflict from a coding artifact without the per-endpoint table.
• The cardiometabolic discussion cites Razny 2021 with P = 0.003 on BMI, but the bundle excerpt reports a primary bone-turnover/CTX-I endpoint with p = 0.043 and does not report a P = 0.003 BMI figure in the excerpt; the Results text cannot be fully verified from the supplied source material without ambiguity about which endpoint the P value refers to.
• The '2669 high-confidence extracted claims' / '2679' figure in the Introduction and claim-count arithmetic (e.g., 251 + 245 + 176 + ... ≈ 2656) does not reconcile transparently across the Evidence Landscape, Evidence Snapshot, and Results tables, making the traceability of the 'claims' metric weaker than the manuscript implies.
• Jorgensen 2026 is a veterinary RCT in diabetic cats; it is repeatedly used in the cardiometabolic outcome class alongside human evidence (Evidence Snapshot, Results) without consistent flags that it is non-human preclinical/veterinary context, despite the Methods noting Jorgensen 2026 'provides animal/preclinical context only' in one sentence. This risks implicit translational conflation.

Minor issues

• The Background section is largely methodological framing rather than scientific background; some readers will expect a substantive biological/clinical rationale paragraph.
• The 'Resolution criteria' sentence at the end of the Discussion is a useful falsifiability anchor but is isolated as a single line; it would read more clearly as a short subsection.
• Some prose (e.g., 'Thermoneutral zone', 'Substrate of adipose-tissue mobilization') uses mechanistic vocabulary without binding it to a specific claim; consider trimming.
• The Houston 2018 finding (lower odds of slow gait speed, OR 0.84) is summarized as 'mixed' or 'unclear' in places, but the bundle excerpt supports a clearer positive direction on this specific functional endpoint; direction-coding should be re-checked.
• The Metabolic-Functional Tradeoff Framework is presented as a paper-level organizing claim with no empirical anchor; it is acceptable as scaffolding but could be tied to one of the cited meta-frameworks (e.g., Ioannidis 2005 surrogate-endpoint caution already cited).

Reviewer note

This is a high-effort, gatekeeper-tier research synthesis with explicit methods, an auditable evidence map, a quantitative evidence index, and substantive cross-domain integration. The structure follows the recommended depth sections (Background, Methods, Results including Findings Map and Evidence Snapshot, Cross-Domain Synthesis, Limitations, Conclusion, plus an explicit Boundary-Condition Matrix and Evidence-Gap Priority), which is rewarded. The cross-domain integration is one of the paper's strongest features: it identifies four to five substantive tensions (cardiometabolic short-duration positive vs longer-horizon null; mechanism vs clinical endpoint; muscle/frailty null beneath positive weight loss; continuous vs intermittent CR; population-baseline-reserve boundary), treats them as boundary conditions, and explicitly refuses to smooth them into a single pooled verdict. The Conclusion and Discussion correctly bound the synthesis: 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence.' This is the right epistemic stance for this corpus and is rewarded, not penalized. The source grounding is generally strong: bundle DOIs/PMIDs exist and plausibly match the cited claims. There is, however, a recurring traceability problem in that several cited p-values in the Results cannot be cleanly located in the supplied bundle excerpts (e.g., Razny 2021 'P = 0.003 on BMI'; the bundle excerpt emphasizes a bone-turnover/CTX-I endpoint with p = 0.043, not BMI). Because the bundles are reference-plus-excerpt (not full text), the reviewer cannot fully verify the P-value claims and the manuscript must either reconcile them or hedge them more explicitly. The arithmetic of the 'claims' total (2669 vs 2679 vs per-source sums) is also inconsistent across sections and weakens the traceability of the quantitative index. The Cross-Domain Synthesis contains a structural defect: the numbering jumps from 'third' to 'fifth,' suggesting an editing artifact. While this does not change the substantive argument, in a publication-grade synthesis it materially weakens the audit trail of the cross-domain map. The load-bearing tension list also conflates source-level direction codes with endpoint-level direction, which risks presenting coding artifacts as evidentiary disagreements. One specific overclaim risk is the inclusion of Jorgensen 2026 (a veterinary diabetic-cat RCT) within the human cardiometabolic outcome class without consistent flagging. The manuscript notes in one place that it 'provides animal/preclinical context only' but it is still aggregated in human outcome tables elsewhere. This is a translational conflation that the manuscript's own separation rules should prevent. The Limitations section is substantive and identifies the surrogate-to-clinical gap, the absence of long-term mortality/hard cardiovascular RCTs in non-diabetic non-obese adults, narrow enrolled populations, single-source endpoints, and the unclosed mechanism-to-clinic chain for cognition and HbA1c. This is materially constraining and rewarded. The Evidence-Gap Priority and Next-Study Design Recommendation sections are specific and actionable. Overall: the paper is closer to accept than reject. The synthesis is genuinely integrated, the conclusions are properly bounded, and the source corpus is real. The required revisions are bounded: numbering consistency, claims-arithmetic reconciliation, sharper per-endpoint traceability for cited P-values, consistent flagging of the veterinary source, and tightening the load-bearing tension list so it uses endpoint-level rather than source-level direction. With these fixes, this is an accept-quality manuscript. As submitted, the structural numbering defect and the claims-arithmetic inconsistency are non-trivial for a manuscript whose central promise is auditability, so a revise decision is warranted.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v12-grounded-integrity